Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' Glossy
Skin-care founder Angela Caglia on the stem cell technology that created 437% sales growth: 'It's transformed the business' Glossy
Abstract Mesenchymal stem cells (MSC) have piqued worldwide interest for their extensive potential to treat a large array of clinical indications, their unique and controversial immunogenic and immune modulatory properties allowing ample discussions and debates for their possible applications. Emerging data demonstrating that the interaction of biomaterials and physical cues with MSC can guide their differentiation into specific cell lineages also provide new interesting insights for further MSC manipulation in different clinical applications. Moreover, recent discoveries of some regulatory molecules and signaling pathways in MSC niche that may regulate cell fate to distinct lineage herald breakthroughs in regenerative medicine. Although the advancement and success in the MSC field had led to an enormous increase in the amount of ongoing clinical trials, we still lack defined clinical therapeutic protocols.
Regenerative Medical Technology Group Announces the Opening of New Clinic in Dubai on November 23 Newswire
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health StockTitan
Stem cell science is dominating the luxury skin-care market as human-derived ingredients become less taboo Glossy
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health The Manila Times
SMART researchers develop a method to enhance effectiveness of cartilage repair therapy MIT News
Abstract Mesenchymal stem cells (MSCs) are isolated from multiple biological tissuesadult bone marrow and adipose tissues and neonatal tissues such as umbilical cord and placenta. In vitro, MSCs show biological features of extensive proliferation ability and multipotency. Moreover, MSCs have trophic, homing/migration and immunosuppression functions that have been demonstrated both in vitro and in vivo. A number of clinical trials are using MSCs for therapeutic interventions in severe degenerative and/or inflammatory diseases, including Crohns disease and graft-versus-host disease, alone or in combination with other drugs.
Lots of efforts have been made to uncover the critical components of the platelet lysate for supporting the MSCs expansion [17,18,19,20,21,22,23,24].
Summary Mesenchymal stem cells (MSCs) were officially named more than 25 years ago to represent a class of cells from human and mammalian bone marrow and periosteum that could be isolated and expanded in culture while maintaining their in vitro capacity to be induced to form a variety of mesodermal phenotypes and tissues.
Recent Comments